Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor ablation cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (83 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 150 | 44% |
| 2020 | 0 | 177 | 46% |
| 2021 | 1 | 191 | 49% |
Percutaneous liver, kidney, lung, and bone tumor ablation. Professional codes (what the surgeon bills): CPT 47382, 47383, 50592, 50593, 32998, 20982, 20983.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Arizona; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 8 | 940−1.6%/yr | −1.6%/yr | 0.3 | 0% | 1,020 in 2030+1.4%/yr |
| Utah | 1 | 173 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 73 | 4,473−1.9%/yr | −1.9%/yr | 6.41.0× | 70% | 4,560 in 2030+0.3%/yr |
| Tumor & fibroid embolization |
Tumor ablation in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
| ≈ 290 |
| – |
| 2026 est. | ≈ 320 | – |
| 2022 | 1 | 184 | 51% |
| 2023 | 2 | 244 | 53% |
| 2024 | 3 | 264 | 54% |
| 2025 from claims | – | 287 232–337 | 55% |
| 2026 forecast | – | 316 247–397 | 55% |
| 2027 forecast | – | 347 257–458 | 56% |
| 2028 forecast | – | 380 269–525 | 56% |
| 2029 forecast | – | 417 284–598 | 57% |
| 2030 forecast | – | 458 300–679 | 57% |
In 2025, 100% hospital outpatient.
| +29%/yr |
| 0.8 |
| 79% |
| 280 in 2030+8.3%/yr |
| Washington | 0 | 149−4.5%/yr | −4.5%/yr | 0.2 | 0% | 40 in 2030−20%/yr |
| Colorado | 0 | 122−2.6%/yr | −2.6%/yr | 0.3 | 0% | 150 in 2030+3.4%/yr |
| Oregon | 0 | 120+0.7%/yr | +0.7%/yr | 0.3 | 0% | 140 in 2030+2.7%/yr |
| 11 |
| 723+24%/yr |
| +24%/yr |
| 1.01.9× |
| 78% |
| 1,640 in 2030+15%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Pulse Biosciences leads with 26% of company spending on these surgeons in 2025, +12 pts on 2024.
In 2025, 19 companies reported engagement with Arizona’s surgeons worth $266K in consulting, speaking, meals and travel tied to these products, about $89K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 5 recalled product lines (3 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.